The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of Worsening Alzheimer's Disease Symptoms after COVID-19 Infection That Were Treated with Yigan-san-gami

COVID-19 감염 후 알츠하이머 치매증상의 악화에 대한 억간산 가미 치험 1례

  • Hyo-jeong Lee (Dept. of Internal Korean Medicine, Dongsuwon Korean Medicine Hospital) ;
  • Sun-woo Kwon (Dept. of Internal Korean Medicine, Dongsuwon Korean Medicine Hospital) ;
  • Yi-jae Kwon (Dept. of Internal Korean Medicine, Dongsuwon Korean Medicine Hospital) ;
  • Jung-min Son (Dept. of Korean Acupuncture & Moxibustion Medicine, Dongsuwon Korean Medicine Hospital) ;
  • Choong-hyun Park (Dept. of Internal Korean Medicine, Dongsuwon Korean Medicine Hospital) ;
  • Ji-yoon Lee (Dept. of Rehabilitation Medicine of Korean Medicine, Dongsuwon Korean Medicine Hospital) ;
  • Jung-eun Lee (Dept. of Internal Korean Medicine, Dongsuwon Korean Medicine Hospital)
  • 이효정 (동수원한방병원 한방내과) ;
  • 권선우 (동수원한방병원 한방내과) ;
  • 권이재 (동수원한방병원 한방내과) ;
  • 손정민 (동수원한방병원 침구의학과) ;
  • 박충현 (동수원한방병원 한방내과) ;
  • 이지윤 (동수원한방병원 한방재활의학과) ;
  • 이정은 (동수원한방병원 한방내과)
  • Received : 2024.04.12
  • Accepted : 2024.05.29
  • Published : 2024.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Introduction: In this case report, we describe the clinical effectiveness of Yigan-san-gami in improving symptoms in a patient with worsening Alzheimer's dementia after COVID-19 infection. Case presentation: Symptoms of dementia worsened in a patient with Alzheimer's disease after COVID-19 infection. Western medicines were added following neurological consultation. However, there was no medicinal effect. The patient was treated with Korean medicine (Yigan-san-gami) three times a day. We used daily charts, the Korean Mini-Mental State Examination-2 (K-MMSE-2), Clinical Dementia Rating (CDR), and Short Version Geriatric Depression Scale (SGDS) to assess the patient's symptoms. Cognitive decline and behavioral and psychological symptoms of dementia (BPSD) improved following the treatment with Yigan-san-gami. Conclusion: The results suggest that Yigan-san-gami may be effective in improving symptoms of Alzheimer's disease that worsen after COVID-19 infection.

Keywords

References

  1. Korean Neurological Association. Textbook of NEUROLOGY. Seoul: PanMun Education; 2017, p. 552-3. 
  2. Al-Sarraj S, Troakes C, Hanley B, Osborn M, Richardson MP, Hotopf M, et al. Invited Review: The spectrum of neuropathology in COVID-19. Neuropathol Appl Neurobiol 2021;47(1):3-16. 
  3. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020;77(6):683-90. 
  4. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021;11(1):16144. 
  5. Chiricosta L, Gugliandolo A, Mazzon E. SARS-CoV-2 Exacerbates Beta-Amyloid Neurotoxicity, Inflammation and Oxidative Stress in Alzheimer's Disease Patients. Int J Mol Sci 2021;22(24):13603. 
  6. Frontera JA, Boutajangout A, Masurkar AV, Betensky RA, Ge Y, Vedvyas A, et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia. Alzheimers Dement 2022;18(5):899-910. 
  7. Boutoleau-Bretonniere C, Pouclet-Courtemanche H, Gillet A, Bernard A, Deruet AL, Gouraud I, et al. The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer's Disease During the COVID-19 Crisis. J Alzheimers Dis 2020;76(1):41-7. 
  8. Hong JH, Kim YS, Park JY, Seok EJ, Rhee YJ, Ahn L, et al. Case Report of Korean Medicine Treatment for Post-COVID-19 Globus Sensation J Int Korean Med 2023;44(2):244-51. 
  9. Oh JH, Song WS, Oh EJ, Lee SH, Park MJ, Lee YJ, et al. A Case Report on a Patient with Aggravated Functional Dyspepsia due to COVID-19 Improved by Korean Medicine Treatment. J Int Korean Med 2023;44(5):875-84. 
  10. Go SA, Yun JY, Jeong JH. Gender Differences in Risk Factor Prevalence and Cognitive Functions in Alzheimer's Disease ; Experience of Ewha Dementia Clinic. Dementia and Neurocognitive Disorders 2007;6(2):34-7. 
  11. Devanand DP, Sano M, Tang Mx, Taylor S, Gurland BJ, Wilder D, et al. Depressed mood and the incidence of Alzheimer's disease in elderly living in the community. Arch Gen Psychiatry 1996;53(2):175-82. 
  12. Szabo MP, Iba M, Nath A, Masliah E, Kim C. Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS. Exp Mol Med 2022;54(4):447-54. 
  13. Joo SH, Hahn CT, Lee CU. The Impact of the COVID-19 Pandemic and Social Distancing on Cognition of Alzheimer's Disease Patients. Psychiatry Investig 2022;19(11):973-80. 
  14. Zifko UA, Yacob M, Braun BJ, Dietz GPH. Alleviation of Post-COVID-19 Cognitive Deficits by Treatment with EGb 761®: A Case Series. Am J Case Rep 2022;23:e937094. 
  15. Han MI, Kim Y, Kim CE, Choi MR. A Short Review of Delirium in Patients With COVID-19. Journal of Korean Geriatric Psychiatry 2021;25(2):65-9. 
  16. Gupta K, Gupta R, Bhatia MS, Tripathi AK, Gupta LK. Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor-α Level in Patients With Major Depressive Disorder With Severe Depression. J Clin Pharmacol 2017;57(12):1519-26. 
  17. The National Alliance on Mental Illness (NAMI). Available from : https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Quetiapine-(Seroquel). 
  18. Cho KH, Kim TH, Jin C, Lee JE, Kwon SW. The Literary Trends of Herbal Prescription Ukgan-san and its Application in Modern Traditional Korean Medicine. Journal of Korean Medicine 2018;39(3):17-27. 
  19. Lee DY, Kim JB, Ha DJ, Kwon CY. Classical, Non-Clinical, and Clinical Evidence of Yokukansan for Alleviating Aggression: Scoping Review. J of Oriental Neuropsychiatry 2021;32(2):111-27. 
  20. Kan'o T, Han JY, Nakahara K, Konno S, Shibata M, Kitahara T, et al. Yokukansan improves distress of medical staff, and cognitive function and motivation in patients with destructive and aggressive behaviors after traumatic brain injury. Acute Med Surg 2014;1(2):88-93. 
  21. Sakamoto S, Ujike H, Takaki M, Mizuki Y, Okahisa Y, Kodama M, et al. Adjunctive yokukansan treatment improved cognitive functions in a patient with schizophrenia. J Neuropsychiatry Clin Neurosci 2013;25(3):E39-40. 
  22. Kang BS, Kim IR, Kim HC, Guk YB, Park YG, Seo BI, et al. Bonchohak. Seoul: Yeongnimsa; 2004, p. 390, 411-5, 684. 
  23. Ito A, Shin N, Tsuchida T, Okubo T, Norimoto H. Antianxiety-like effects of Chimpi (dried citrus peels) in the elevated open-platform test. Molecules 2013;18(8):10014-23. 
  24. Kennedy SH. Agomelatine: efficacy at each phase of antidepressant treatment. CNS Drugs 2009;23 Suppl 2:41-7. 
  25. Okahara K, Ishida Y, Hayashi Y, Inoue T, Tsuruta K, Takeuchi K, et al. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(3):532-6.